China's medical products administrator accepted Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Chongqing Kailin Pharmaceutical's drug registration application for its sodium thiosulfate injection, according to a Friday filing with the Shanghai Stock Exchange.
The drug is an antidote for cyanide poisoning, and can also be used for arsenic, mercury, lead, bismuth, iodine and other types of poisoning, the filing said.
Shares rose 1% in Hong Kong on Monday afternoon.
Price (HKD): $23.58, Change: $+0.20, Percent Change: +0.86%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments